Home Newsfeeds Needham Maintains Buy on Conmed, Lowers Price Target to $123

Needham Maintains Buy on Conmed, Lowers Price Target to $123

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

Toyota Gets $841M Support From Japan To Boost Domestic EV Battery Capacity: Report

By Shivani Kumaresan

June 16, 8:43 AM

Toyota Motor Corp (NYSE: TM) will reportedly receive up to $841 million in subsidies from the Japanese government to boost domestic production of batteries for electric vehicles.

Piper Sandler Initiates Coverage On Avidbank Holdings with Overweight Rating, Announces Price Target of $24

By Benzinga Newsdesk

August 25, 6:22 AM

Piper Sandler analyst Andrew Liesch initiates coverage on Avidbank Holdings (OTC:AVBH) with a Overweight rating and announces Price Target of $24.

AVBH

Sarepta Therapeutics Announces Sale Of Priority Review Voucher For $102M

By Happy Mohamed

July 5, 8:32 AM

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta

SRPT